RET inhibitors such as selpercatinib and pralsetinib target the abnormal RET protein, while MET inhibitors such as capmatinib and tepotinib can be used to treat metastatic NSCLC characterized by MET gene mutations [13]. This evidence concerns the gene MET and non-small cell lung carcinoma.